Therapeutic approaches for HTLV-1-associated adult T-cell leukemia/lymphoma: a comprehensive review.
ATLL
Chemotherapy
Clinical features
HTLV-1
Monoclonal antibodies
Stem cell transplantation
Targeting surface molecules
Treatment
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
09 Sep 2023
09 Sep 2023
Historique:
received:
03
07
2023
accepted:
18
08
2023
medline:
11
9
2023
pubmed:
10
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
Adult T-cell leukemia/lymphoma (ATLL), an infrequent malignancy resultant from human T-cell lymphotropic virus type I (HTLV-1), exhibits a spectrum of phenotypes, encompassing acute, smoldering, lymphomatous, and chronic variants, each bearing distinct clinical presentations. The preponderant acute manifestation is characterized by hypercalcemia, systemic manifestations, organomegaly, and dermatological eruptions. Conversely, the chronic phenotype is typified by lymphocytosis and/or cutaneous eruptions, while smoldering ATLL assumes an asymptomatic course. Immunocompromise afflicts ATLL patients, heightening their vulnerability to opportunistic infections that frequently intricately intertwine with disease progression. Therefore, an early diagnosis is crucial to manage the disease appropriately. While conventional chemotherapeutic regimens have shown limited success, especially in acute and lymphoma types, recent studies suggest that allogeneic stem cell transplantation might enhance treatment results because it has shown promising outcomes in some patients. Novel therapeutics, such as interferon and monoclonal antibodies, have also shown promise, but more research is needed to confirm their efficacy. Moreover, the identification of biomarkers for ATLL and genetic changes in HTLV-1 infected cells has led to the development of targeted therapies that have shown remarkable success in clinical trials. These targeted therapies have the potential to offer a more personalized approach to the treatment of ATLL. The aim of our review is to elaborate on conventional and novel therapies and the efficiency of mentioned treatments.
Identifiants
pubmed: 37689806
doi: 10.1007/s12032-023-02166-8
pii: 10.1007/s12032-023-02166-8
doi:
Substances chimiques
Antibodies, Monoclonal
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
295Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Ishikawa C, Senba M, Mori N. Evaluation of artesunate for the treatment of adult T-cell leukemia/lymphoma. Eur J Pharmacol. 2020;872: 172953.
pubmed: 31996318
doi: 10.1016/j.ejphar.2020.172953
Ohno R, Masaoka T, Shirakawa S, Sakamoto S, Hirano M, Hanada S, et al. Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis (2, 6-dioxopiperazine). Cancer. 1993;71(7):2217–21.
pubmed: 8384067
doi: 10.1002/1097-0142(19930401)71:7<2217::AID-CNCR2820710709>3.0.CO;2-8
Uozumi K. Treatment of adult T-cell leukemia. J Clin Exp Hematop. 2010;50(1):9–25.
pubmed: 20505272
doi: 10.3960/jslrt.50.9
Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28(9):1591–8.
pubmed: 20177026
doi: 10.1200/JCO.2009.25.3575
Ceesay MM, Matutes E, Taylor GP, Fields P, Cavenagh J, Simpson S, et al. Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL). Leuk Res. 2012;36(7):857–61.
pubmed: 22209076
doi: 10.1016/j.leukres.2011.12.004
Ishitsuka K, Tamura K. Treatment of adult T-cell leukemia/lymphoma: past, present, and future. Eur J Haematol. 2008;80(3):185–96.
pubmed: 18081707
doi: 10.1111/j.1600-0609.2007.01016.x
El Hajj H, Tsukasaki K, Cheminant M, Bazarbachi A, Watanabe T, Hermine O. Novel treatments of adult T cell leukemia lymphoma. Front Microbiol. 2020;11:1062.
pubmed: 32547515
pmcid: 7270167
doi: 10.3389/fmicb.2020.01062
Fujikawa D, Nakagawa S, Hori M, Kurokawa N, Soejima A, Nakano K, et al. Polycomb-dependent epigenetic landscape in adult T-cell leukemia. Blood J Am Soc Hematol. 2016;127(14):1790–802.
Dou F, Tian Z, Yang X, Li J, Wang R, Gao J. Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma. Drug Discoveries Therapeutics. 2022;16(6):297–9.
pubmed: 36310058
doi: 10.5582/ddt.2022.01085
Hanada S, Uematsu T, Iwahashi M, Nomura K, Utsunomiya A, Kodama M, et al. The prevalence of human T-cell leukemia virus type I infection in patients with hematologic and nonhematologic diseases in an adult T-cell leukemia-endemic area of Japan. Cancer. 1989;64(6):1290–5.
pubmed: 2766224
doi: 10.1002/1097-0142(19890915)64:6<1290::AID-CNCR2820640620>3.0.CO;2-Z
Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014;15(11):e517–26.
pubmed: 25281470
doi: 10.1016/S1470-2045(14)70202-5
Cook LB, Phillips AA. How i treat adult t-cell leukemia/lymphoma. Blood. 2021;137(4):459–70.
pubmed: 33075812
doi: 10.1182/blood.2019004045
Kawano R, Utsunomiya A, Matsuoka H, Kawano F, Ikeda S, Izumi Y, et al. Registration of hematological disorders by the Kyushu Hematology Organization for Treatment (K-HOT) Study Group. Japanese J Clin Hematol. 2004;45(6):478–80.
Proietti FA, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24(39):6058–68.
pubmed: 16155612
doi: 10.1038/sj.onc.1208968
Ramezani S, Rezaee SA, Farjami Z, Ebrahimi N, Abdullabass HK, Jebur MII, et al. HTLV, a multi organ oncovirus. Microb Pathog. 2022. https://doi.org/10.1016/j.micpath.2022.105622 .
doi: 10.1016/j.micpath.2022.105622
pubmed: 35690233
pmcid: 9176176
Mozhgani SH, Zarei-Ghobadi M, Teymoori-Rad M, Mokhtari-Azad T, Mirzaie M, Sheikhi M, et al. Human T-lymphotropic virus 1 (HTLV-1) pathogenesis: a systems virology study. J Cell Biochem. 2018;119(5):3968–79.
pubmed: 29227540
doi: 10.1002/jcb.26546
Tamaki T, Karube K, Sakihama S, Tsuruta Y, Awazawa R, Hayashi M, et al. A Comprehensive study of the immunophenotype and its clinicopathologic significance in adult T-Cell leukemia/lymphoma. Mod Pathol. 2023;36(8): 100169.
pubmed: 36997002
doi: 10.1016/j.modpat.2023.100169
Kawano R, Niino D, Ohshima K. Six cases of CD20-positive adult T-cell leukemia. J Clin Exp Hematop. 2016;56(2):119–25.
pubmed: 27980301
pmcid: 6144208
doi: 10.3960/jslrt.56.119
Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, Izawa D, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1–transformed T cells. Blood. 2002;99(5):1505–11.
pubmed: 11861261
doi: 10.1182/blood.V99.5.1505
Nozuma S, Matsuura E, Tanaka M, Kodama D, Matsuzaki T, Yoshimura A, et al. Identification and tracking of HTLV-1-infected T cell clones in virus-associated neurologic disease. JCI Insight. 2023. https://doi.org/10.1172/jci.insight.167422 .
doi: 10.1172/jci.insight.167422
pubmed: 37036006
pmcid: 10132145
Karube K, Ohshima K, Tsuchiya T, Yamaguchi T, Kawano R, Suzumiya J, et al. Expression of FoxP3, a key molecule in CD4+ CD25+ regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol. 2004;126(1):81–4.
pubmed: 15198736
doi: 10.1111/j.1365-2141.2004.04999.x
Araya N, Sato T, Ando H, Tomaru U, Yoshida M, Coler-Reilly A, et al. HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells. J Clin Investig. 2014;124(8):3431–42.
pubmed: 24960164
pmcid: 4109535
doi: 10.1172/JCI75250
Olson DP, Taylor BJ, La M, Sather H, Reaman GH, Ivy SP. The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children’s Oncology Group. Leuk Lymphoma. 2005;46(5):681–91.
pubmed: 16019505
doi: 10.1080/10428190500032612
Hoshino H. Cellular factors involved in HTLV-1 entry and pathogenicit. Front Microbiol. 2012;3:222.
pubmed: 22737146
pmcid: 3380293
doi: 10.3389/fmicb.2012.00222
Jones KS, Petrow-Sadowski C, Huang YK, Bertolette DC, Ruscetti FW. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4+ T cells. Nat Med. 2008;14(4):429–36.
pubmed: 18376405
doi: 10.1038/nm1745
Eusebio-Ponce E, Anguita E, Paulino-Ramirez R, Candel FJ. HTLV-1 infection an emerging risk. Pathogenesis, epidemiology, diagnosis and associated diseases. Revista Española Quimioterapia. 2019;32(6):485.
Pique C, Jones K. Pathways of cell-cell transmission of HTLV-1. Front Microbiol. 2012;3:378.
pubmed: 23109932
pmcid: 3479854
doi: 10.3389/fmicb.2012.00378
Carpentier A, Barez PY, Hamaidia M, Gazon H, de Brogniez A, Perike S, et al. Modes of Human T Cell Leukemia Virus Type 1 Transmission. Replication Persistence Viruses. 2015;7(7):3603–24.
pubmed: 26198240
Gross C, Thoma-Kress AK. Molecular mechanisms of HTLV-1 cell-to-cell transmission. Viruses. 2016;8(3):74.
pubmed: 27005656
pmcid: 4810264
doi: 10.3390/v8030074
Matutes E. Adult T-cell leukaemia/lymphoma. J Clin Pathol. 2007;60(12):1373–7.
pubmed: 18042693
pmcid: 2095573
doi: 10.1136/jcp.2007.052456
Yamaguchi K, Matutes E, Catovsky D, Galton D, Nakada K, Takatsuki K. Strongyloides stercoralis as candidate co-factor for HTLV-I-induced leukaemogenesis. The Lancet. 1987;330(8550):94–5.
doi: 10.1016/S0140-6736(87)92752-8
Stewart DM, Ramanathan R, Mahanty S, Fedorko DP, Janik JE, Morris JC. Disseminated strongyloides stercoralis infection in HTLV-1-associated adult t-cell leukemia/lymphoma. Acta Haematol. 2011;126(2):63–7.
pubmed: 21474923
pmcid: 3080579
doi: 10.1159/000324799
Bunn PA Jr, Foss FM. T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). J Cell Biochem. 1996;63(S24):12–23.
doi: 10.1002/jcb.240630503
Karthik U, Ganesan P, Sagar TG, Cyriac S, Majhi U. Adult T-cell leukemia in India: report of two cases and review of literature. J Cancer Res Ther. 2011;7(3):338–40.
pubmed: 22044818
doi: 10.4103/0973-1482.86999
Kao D-E, Chen C-P, Fang K-T, Hsu Y-H, Hung S-J. A rare presentation of adult T-cell leukemia/lymphoma with generalized cutaneous purpuric lesions. Dermatol Sin. 2015;33(4):234–8.
doi: 10.1016/j.dsi.2015.02.003
Nagashima T, Mori M, Fujimoto M, Nunomura M, Sakurai Y, Okada Y, et al. Adult T-cell lymphoma involving the leptomeninges associated with a spinal cord schwannoma. Neuropathology. 2001;21(3):229–35.
pubmed: 11666021
doi: 10.1046/j.1440-1789.2001.00391.x
Bazarbachi A, Merhi RA, Gessain A, Talhouk R, El-Khoury H, Nasr R, et al. Human T-cell lymphotropic virus type I-infected cells extravasate through the endothelial barrier by a local angiogenesis-like mechanism. Can Res. 2004;64(6):2039–46.
doi: 10.1158/0008-5472.CAN-03-2390
Shimoyama M, Group LS. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984–87). Br J Haematol. 1991;79(3):428–37.
doi: 10.1111/j.1365-2141.1991.tb08051.x
Taguchi H, Kinoshita K-I, Takatsuki K, Tomonaga M, Araki K, Arima N, et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquired Immune Deficiency Syndromes. 1996;12(2):182–6.
doi: 10.1097/00042560-199606010-00012
Matsushita K, Matsumoto T, Ohtsubo H, Fujiwara H, Imamura N, Hidaka S, et al. Long-term maintenance combination chemotherapy with OPECMPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemialymphoma. Leuk Lymphoma. 1999;36(1–2):67–75.
pubmed: 10613451
doi: 10.3109/10428199909145950
Tsuda H, Takatsuki K, Ohno R, Masaoka T, Okada K, Shirakawa S, et al. Treatment of adult T-cell leukaemia–lymphoma with irinotecan hydrochloride (CPT-11). Br J Cancer. 1994;70(4):771–4.
pubmed: 7917938
pmcid: 2033383
doi: 10.1038/bjc.1994.394
Ichimaru M, Kamihira S, Moriuchi Y, Kuraishi Y, Usui N, Toki H, et al. Clinical study on the effect of natural alpha-interferon (HLBI) in the treatment of adult T-cell leukemia. Gan to Kagaku ryoho Cancer and Chemotherapy. 1988;15(10):2975–81.
pubmed: 3052302
Yoshie O. CCR4 as a therapeutic target for cancer immunotherapy. Cancers. 2021;13(21):5542.
pubmed: 34771703
pmcid: 8583476
doi: 10.3390/cancers13215542
Ishida T, Ueda R. Antibody therapy for Adult T-cell leukemia–lymphoma. Int J Hematol. 2011;94:443–52.
pubmed: 21993874
doi: 10.1007/s12185-011-0941-5
Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphomakw-0761 as a novel immunotherapeutic agent for ATLL. Clin Cancer Res. 2010;16(5):1520–31.
pubmed: 20160057
doi: 10.1158/1078-0432.CCR-09-2697
Yoshie O, Matsushima K. CCR4 and its ligands: from bench to bedside. Int Immunol. 2015;27(1):11–20.
pubmed: 25087232
doi: 10.1093/intimm/dxu079
Ureshino H, Kamachi K, Kimura S. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma. Clin Lymphoma Myeloma Leuk. 2019;19(6):326–31.
pubmed: 30981611
doi: 10.1016/j.clml.2019.03.004
Ollila TA, Sahin I, Olszewski AJ. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma. Onco Targets Ther. 2019;12:1085.
pubmed: 30799938
pmcid: 6369856
doi: 10.2147/OTT.S165615
Subramaniam JM, Whiteside G, McKeage K, Croxtall JC. Mogamulizumab: first global approval. Drugs. 2012;72:1293–8.
pubmed: 22686619
doi: 10.2165/11631090-000000000-00000
Yoshimitsu M, Arima N. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma. Blood and Lymphatic Cancer: Targets and Therapy. 2014:17–23.
Duvic M, Pinter-Brown L, Foss FM, Sokol L, Jorgensen J, Spitalny GL, et al. Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. Blood. 2010;116(21):962.
doi: 10.1182/blood.V116.21.962.962
Suehiro Y, Hasegawa A, Iino T, Sasada A, Watanabe N, Matsuoka M, et al. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study. Br J Haematol. 2015;169(3):356–67.
pubmed: 25612920
doi: 10.1111/bjh.13302
Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac [see comments]. 1995.
Berkowitz JL, Janik JE, Stewart DM, Jaffe ES, Stetler-Stevenson M, Shih JH, et al. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clin Immunol. 2014;155(2):176–87.
pubmed: 25267440
pmcid: 4306230
doi: 10.1016/j.clim.2014.09.012
Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol. 2002;19:S27–32.
pubmed: 12180489
doi: 10.1385/MO:19:2S:S27
Ravandi F, Aribi A, O’Brien S, Faderl S, Jones D, Ferrajoli A, et al. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009;27(32):5425.
pubmed: 19805674
pmcid: 4881363
doi: 10.1200/JCO.2009.22.6688
Callens C, Moura I, Lepelletier Y, Coulon S, Renand A, Dussiot M, et al. Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody. Leukemia. 2008;22(1):42–8.
pubmed: 17898788
doi: 10.1038/sj.leu.2404958
Maeda N, Muta H, Oflazoglu E, Yoshikai Y. Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo. Cancer Sci. 2010;101(1):224–30.
pubmed: 19799612
doi: 10.1111/j.1349-7006.2009.01354.x
Chen J, Zhang M, Ju W, Waldmann TA. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. Blood. 2009;113(6):1287–93.
pubmed: 18948574
pmcid: 2637191
doi: 10.1182/blood-2008-04-149658
Kawashiri SY, Nakamura H, Origuchi T, Aoyagi K, Kawakami A. Ultrasonography and magnetic resonance imaging findings of rheumatoid arthritis-like arthritis in a patient with adult T-cell leukemia. Mod Rheumatol. 2016;26(6):971–5.
pubmed: 25119259
doi: 10.3109/14397595.2014.948529
Tsukasaki K, Maeda T, Arimura K, Taguchi J, Fukushima T, Miyazaki Y, et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. Bone Marrow Transplant. 1999;23(1):87–9.
pubmed: 10037056
doi: 10.1038/sj.bmt.1701533
Utsunomiya A, Miyazaki Y, Takatsuka Y, Hanada S, Uozumi K, Yashiki S, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27(1):15–20.
pubmed: 11244433
doi: 10.1038/sj.bmt.1702731
Fukushima T, Miyazaki Y, Honda S, Kawano F, Moriuchi Y, Masuda M, et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia. 2005;19(5):829–34.
pubmed: 15744352
doi: 10.1038/sj.leu.2403682
Kenji I, Kazuo T. Treatment of adult T-cell leukemia/lymphoma: past, present, and future. Eur J Haematol. 2008;80(3):185–96.
doi: 10.1111/j.1600-0609.2007.01016.x
Fujiwara H, Arima N, Akasaki Y, Ohtsubo H, Ozaki A, Kukita T, et al. Interferon-α therapy following autologous peripheral blood stem cell transplantation for adult T cell leukemia/lymphoma. Acta Haematol. 2002;107(4):213–9.
pubmed: 12053149
doi: 10.1159/000058317
Makoto H, Midori G, Masahiko O, Ken-Ichi A, Noriaki K, Tsukasa N, et al. Mogamulizumab for post-transplant relapse of adult t-cell leukemia/lymphoma: a case study. Int J Hematol. 2022;117(1):143–8.
Shigeo F, Yoshitaka I, Atae U, Yukiyoshi M, Kaoru U, Ilseung C, et al. Pretransplantation anti-Ccr4 antibody mogamulizumab against adult t-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426–33.
doi: 10.1200/JCO.2016.67.8250
Rihab N, El Hiba H, Youmna K, Olivier H, Ali B. Controversies in targeted therapy of adult t cell leukemia/lymphoma: ON Target or OFF target effects? Viruses. 2011;3(6):750–69.
doi: 10.3390/v3060750
Laribi K, Alani M, Truong C, Baugier de Materre A. Recent advances in the treatment of peripheral T-cell lymphoma. Oncologist. 2018;23(9):1039–53.
pubmed: 29674443
pmcid: 6192612
doi: 10.1634/theoncologist.2017-0524
Siegall CB. Seattle Genetics, Inc.
Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32(28):3137.
pubmed: 25135998
pmcid: 4171358
doi: 10.1200/JCO.2013.54.2456
Hermine O, Ramos JC, Tobinai K. A review of new findings in adult T-cell leukemia–lymphoma: a focus on current and emerging treatment strategies. Adv Ther. 2018;35:135–52.
pubmed: 29411267
pmcid: 5818559
doi: 10.1007/s12325-018-0658-4
Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O’Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood J Am Soc Hematol. 2014;123(20):3095–100.
Oka S, Ono K, Nohgawa M. Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia. Anticancer Drugs. 2020;31(5):536–9.
pubmed: 31934889
doi: 10.1097/CAD.0000000000000895
Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, et al. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma. 2014;55(10):2328–34.
pubmed: 24359243
doi: 10.3109/10428194.2013.876496
Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2(1):1–10.
doi: 10.1186/1756-8722-2-36
Ogura M, Imaizumi Y, Uike N, Asou N, Utsunomiya A, Uchida T, et al. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. Lancet Haematol. 2016;3(3):e107–18.
pubmed: 26947199
doi: 10.1016/S2352-3026(15)00284-7
Corporation. C. REVLIMID®(Lenalidomide)[prescribing information]. 2006.
Ramos JC, Chapman JR, Komanduri KV, Barber GN. Trial in progress: a phase ii trial of belinostat as consolidation therapy with zidovudine for adult T-cell leukemia-lymphoma (ATLL). Blood. 2021;138:2477.
doi: 10.1182/blood-2021-148650
Fields PA, Taylor GP. “Antivirals” in the treatment of adult T cell Leukaemia-Lymphoma (ATLL). Curr Hematol Malig Rep. 2012;7:267–75.
pubmed: 23093306
doi: 10.1007/s11899-012-0139-9
Shibata D, Brynes RK, Rabinowitz A, Hanson CA, Slovak ML, Spira TJ, et al. Human T-cell lymphotropic virus type I (HTLV-I)-associated adult T-cell leukemia-lymphoma in a patient infected with human immunodeficiency virus type 1 (HIV-1). Ann Intern Med. 1989;111(11):871–5.
pubmed: 2573306
doi: 10.7326/0003-4819-111-11-871
Hodson A, Crichton S, Montoto S, Mir N, Matutes E, Cwynarski K, et al. Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. J Clin Oncol. 2011;29(35):4696–701.
pubmed: 22042945
doi: 10.1200/JCO.2011.35.5578
Hermine O, Allard I, Lévy V, Arnulf B, Gessain A, Bazarbachi A. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J. 2002;3(6):276–82.
pubmed: 12522449
doi: 10.1038/sj.thj.6200195
Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28(27):4177–83.
pubmed: 20585095
doi: 10.1200/JCO.2010.28.0669
Kinpara S, Kijiyama M, Takamori A, Hasegawa A, Sasada A, Masuda T. Interferon-a (IFN-a) suppresses HTLV-1 gene expression and cell cycling, while IFN-a combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells. Retrovirology. 2013;10(10):52.
pubmed: 23688327
pmcid: 3698133
doi: 10.1186/1742-4690-10-52
Macchi B, Balestrieri E, Frezza C, Grelli S, Valletta E, Marçais A, et al. Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α. Blood Adv. 2017;1(12):748.
pubmed: 29296718
pmcid: 5728049
doi: 10.1182/bloodadvances.2016001370
Malpica L, Pimentel A, Reis IM, Gotuzzo E, Lekakis L, Komanduri K, et al. Epidemiology, clinical features, and outcome of HTLV-1–related ATLL in an area of prevalence in the United States. Blood Adv. 2018;2(6):607–20.
pubmed: 29545256
pmcid: 5873228
doi: 10.1182/bloodadvances.2017011106
Yamagishi M, Hori M, Fujikawa D, Ohsugi T, Honma D, Adachi N, et al. Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep. 2019;29(8):2321-37.e7.
pubmed: 31747604
doi: 10.1016/j.celrep.2019.10.083
Yamagishi M, Fujikawa D, Honma D, Adachi N, Nakagawa S, Hori M, et al. Polycomb-dependent epigenetic landscape in adult T cell leukemia (ATL); providing proof of concept for targeting EZH1/2 to selectively eliminate the HTLV-1 infected population. Am Soc Hematol Washington. 2015. https://doi.org/10.1182/blood.V126.23.572.572 .
doi: 10.1182/blood.V126.23.572.572
Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13(1):1–12.
doi: 10.1186/s13045-020-00937-8
Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, et al. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma. Blood J Am Soc Hematol. 2023;141(10):1159–68.
Hull EE, Montgomery MR, Leyva KJ. HDAC inhibitors as epigenetic regulators of the immune system: impacts on cancer therapy and inflammatory diseases. Biomed Res Int. 2016. https://doi.org/10.1155/2016/8797206 .
doi: 10.1155/2016/8797206
pubmed: 27556043
pmcid: 4983322
San José-Enériz E, Gimenez-Camino N, Agirre X, Prosper F. HDAC inhibitors in acute myeloid Leukemia. Cancers. 2019;11(11):1794.
pubmed: 31739588
pmcid: 6896008
doi: 10.3390/cancers11111794
Grant PA. A tale of histone modifications. Genome Biol. 2001;2:1–6.
doi: 10.1186/gb-2001-2-4-reviews0003
Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017;18(7):1414.
pubmed: 28671573
pmcid: 5535906
doi: 10.3390/ijms18071414
Nishioka C, Ikezoe T, Yang J, Komatsu N, Bandobashi K, Taniguchi A, et al. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor κB. Leuk Res. 2008;32(2):287–96.
pubmed: 17644177
doi: 10.1016/j.leukres.2007.05.026
Sin C-f, P-hM M. The role of proteasome inhibitors in treating acute lymphoblastic Leukaemia. Front Oncol. 2021;11:5450.
doi: 10.3389/fonc.2021.802832
Fogli S, Galimberti S, Gori V, Del Re M, Danesi R. Pharmacology differences among proteasome inhibitors: implications for their use in clinical practice. Pharmacol Res. 2021;167: 105537.
pubmed: 33684510
doi: 10.1016/j.phrs.2021.105537
Tan CRC, Abdul-Majeed S, Cael B, Barta SK. Clinical pharmacokinetics and pharmacodynamics of bortezomib. Clin Pharmacokinet. 2019;58:157–68.
pubmed: 29802543
doi: 10.1007/s40262-018-0679-9
Horton TM, Gannavarapu A, Blaney SM, D’Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006;58(1):13–23.
pubmed: 16292537
doi: 10.1007/s00280-005-0135-z
Hu X, Xu J, Sun A, Shen Y, He G, Guo F. Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-κB activity. Leuk Lymphoma. 2011;52(12):2393–5.
pubmed: 21745166
doi: 10.3109/10428194.2011.593271
Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children’s Oncology Group study. Clin Cancer Res. 2007;13(5):1516–22.
pubmed: 17332297
doi: 10.1158/1078-0432.CCR-06-2173
Koyama D, Kikuchi J, Hiraoka N, Wada T, Kurosawa H, Chiba S, et al. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. Leukemia. 2014;28(6):1216–26.
pubmed: 24301524
pmcid: 4051216
doi: 10.1038/leu.2013.366
Huang C, Hu X, Wang L, Lü S, Cheng H, Song X, et al. Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro. Cancer Chemother Pharmacol. 2012;70:801–9.
pubmed: 22996635
doi: 10.1007/s00280-012-1953-4
Zhang L-l, Wei J-y, Wang L, Huang S-l, Chen J-l. Human T-cell lymphotropic virus type 1 and its oncogenesis. Acta Pharmacol Sin. 2017;38(8):1093–103.
pubmed: 28392570
pmcid: 5547553
doi: 10.1038/aps.2017.17
Murata S, Takahama Y, Kasahara M, Tanaka K. The immunoproteasome and thymoproteasome: functions, evolution and human disease. Nat Immunol. 2018;19(9):923–31.
pubmed: 30104634
doi: 10.1038/s41590-018-0186-z
Rank CU, Schmiegelow K. Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020. Semin Hematol. 2020;57(3):102–14.
pubmed: 33256899
doi: 10.1053/j.seminhematol.2020.08.001
Jenkins TW, Downey-Kopyscinski SL, Fields JL, Rahme GJ, Colley WC, Israel MA, et al. Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein. Sci Rep. 2021;11(1):10883.
pubmed: 34035431
pmcid: 8149845
doi: 10.1038/s41598-021-90451-9
da Mota THA, Camargo R, Biojone ER, Guimarães AFR, Pittella-Silva F, de Oliveira DM. The relevance of telomerase and telomere-associated proteins in B-acute lymphoblastic Leukemia. Genes. 2023;14(3):691.
pubmed: 36980962
pmcid: 10048576
doi: 10.3390/genes14030691
Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 2002;7(1):9–16.
pubmed: 11854543
doi: 10.1634/theoncologist.7-1-9
Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood J Am Soc Hematol. 2002;100(5):1715–20.
Zimmerman B, Sargeant A, Landes K, Fernandez SA, Chen C-S, Lairmore MD. Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma. Leuk Res. 2011;35(11):1491–7.
pubmed: 21802726
pmcid: 3191315
doi: 10.1016/j.leukres.2011.07.015
Kannagi M, Hasegawa A, Nagano Y, Kimpara S, Suehiro Y. Impact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL. Retrovirology. 2019;16(1):23.
pubmed: 31438973
pmcid: 6704564
doi: 10.1186/s12977-019-0484-z
Kannagi M, Hasegawa A, Nagano Y, Iino T, Okamura J, Suehiro Y. Maintenance of long remission in adult T-cell leukemia by Tax-targeted vaccine: a hope for disease-preventive therapy. Cancer Sci. 2019;110(3):849–57.
pubmed: 30666755
pmcid: 6398881
doi: 10.1111/cas.13948
Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27(3):453–9.
pubmed: 19064971
pmcid: 2737379
doi: 10.1200/JCO.2008.18.2428
Bazarbachi A, Suarez F, Fields P, Hermine O. How I treat adult T-cell leukemia/lymphoma. Blood. 2011;118(7):1736–45.
pubmed: 21673346
doi: 10.1182/blood-2011-03-345702
Jafari Maskouni E, Jamalvandi T, Tabatabaei F, Bourenjan Shirazi S, Saadati H, Letafati A, et al. Association between Epstein-Bar virus and colorectal cancer: a systematic review and meta-analysis. Microb Pathog. 2023;179: 106087.
pubmed: 37003501
doi: 10.1016/j.micpath.2023.106087
Ghorbani S, Tambrchi V, Farzi R, Khatami A, Samiei RN, Saadati H, et al. Association between human Epstein-Barr virus and brain cancer: a systematic review and meta-analysis. Futur Virol. 2023;18(8):537–45.
doi: 10.2217/fvl-2022-0219
Katsuya H. Current and emerging therapeutic strategies in adult T-cell leukemia–lymphoma. Int J Hematol. 2023;117(4):512–22.
pubmed: 36862273
doi: 10.1007/s12185-023-03572-4
Kchour G, Makhoul NJ, Mahmoudi M, Kooshyar M-M, Shirdel A, Rastin M, et al. Zidovudine and interferon-α treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leuk Lymphoma. 2007;48(2):330–6.
pubmed: 17325893
doi: 10.1080/10428190601071717
Waldmann TA, White JD, Goldman CK, Top L, Grant A, Bamford R, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood. 1993. https://doi.org/10.1182/blood.V82.6.1701.bloodjournal8261701 .
doi: 10.1182/blood.V82.6.1701.bloodjournal8261701
pubmed: 8400227
Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4+ CD25+ regulatory T cells. J Exp Med. 2001;194(6):847–54.
pubmed: 11560999
pmcid: 2195967
doi: 10.1084/jem.194.6.847
Yu P, Petrus MN, Ju W, Zhang M, Conlon KC, Nakagawa M, et al. Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model. Leukemia. 2015;29(3):556–66.
pubmed: 25118879
doi: 10.1038/leu.2014.241
Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(27):4293–7.
pubmed: 17709797
doi: 10.1200/JCO.2007.11.4207
Krem MM, Press OW, Horwitz MS, Tidwell T. Mechanisms and clinical applications of chromosomal instability in lymphoid malignancy. Br J Haematol. 2015;171(1):13–28.
pubmed: 26018193
doi: 10.1111/bjh.13507
Mihara K, Yoshida T, Ishida S, Takei Y, Kitanaka A, Shimoda K, et al. All-trans retinoic acid and interferon-α increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors. Blood Cancer J. 2016;6(5): e421.
pubmed: 27176797
pmcid: 4916299
doi: 10.1038/bcj.2016.30
Huey MG, Minson KA, Earp HS, DeRyckere D, Graham DK. Targeting the TAM receptors in Leukemia. Cancers. 2016;8(11):101.
pubmed: 27834816
pmcid: 5126761
doi: 10.3390/cancers8110101